Fujian Haixi Pharmaceuticals Co., Ltd. is a commercial-stage pharmaceutical company dedicated to the research, development, manufacturing, and sale of pharmaceutical products in China. Established in 2012 and headquartered in Fuzhou, the company maintains a diversified portfolio that spans both generic and innovative therapeutic solutions for major diseases affecting oncology, digestive, cardiovascular, endocrine, neurological, and inflammatory systems. Its commercialized business primarily comprises generics addressing leading medical needs, while its research pipeline features internally developed, proprietary drug candidates, including prospective first-in-class assets in oncology and ophthalmology. Fujian Haixi Pharmaceuticals serves China's largest therapeutic areas, which collectively represented over a quarter of the nation’s pharmaceutical market in recent years. With a business model that integrates research and commercial execution, the firm collaborates with retail and online pharmacies as well as internet-based medical platforms, helping to make advanced medicines widely accessible. The company is recognized for its asset-light approach, focusing on addressing unmet clinical needs through small-molecule drugs and fostering innovation with a vision toward global market relevance.